A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease

Leonardo J. Solmesky, Netaly Khazanov, Hanoch Senderowitz, Peixiang Wang, Berge A. Minassian, Igor M. Ferreira, Wyatt W. Yue, Alexander Lossos, Miguel Weil, Or Kakhlon

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Glycogen storage disorders (GSDs) are caused by excessive accumulation of glycogen. Some GSDs [adult polyglucosan (PG) body disease (APBD), and Tarui and Lafora diseases] are caused by intracellular accumulation of insoluble inclusions, called PG bodies (PBs), which are chiefly composed of malconstructed glycogen. We developed an APBD patient skin fibroblast cell-based assay for PB identification, where the bodies are identified as amylase-resistant periodic acid–Schiff’s-stained structures, and quantified. We screened the DIVERSet CL 10 084 compound library using this assay in high-throughput format and discovered 11 dose-dependent and 8 non-dose-dependent PB-reducing hits. Approximately 70% of the hits appear to act through reducing glycogen synthase (GS) activity, which can elongate glycogen chains and presumably promote PB generation. Some of these GS inhibiting hits were also computationally predicted to be similar to drugs interacting with the GS activator protein phosphatase 1. Our work paves the way to discovering medications for the treatment of PB-involving GSD, which are extremely severe or fatal disorders.

Original languageEnglish (US)
Pages (from-to)3403-3420
Number of pages18
JournalBiochemical Journal
Volume474
Issue number20
DOIs
StatePublished - Oct 15 2017

Fingerprint

High-Throughput Screening Assays
Glycogen
Assays
Screening
Throughput
Glycogen Synthase
Glycogen Storage Disease Type VII
Lafora Disease
Therapeutics
Protein Phosphatase 1
Transcription Factor AP-1
Fibroblasts
Amylases
Libraries
polyglucosan
Adult Form Polyglucosan Body Disease
Skin
Cells
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease. / Solmesky, Leonardo J.; Khazanov, Netaly; Senderowitz, Hanoch; Wang, Peixiang; Minassian, Berge A.; Ferreira, Igor M.; Yue, Wyatt W.; Lossos, Alexander; Weil, Miguel; Kakhlon, Or.

In: Biochemical Journal, Vol. 474, No. 20, 15.10.2017, p. 3403-3420.

Research output: Contribution to journalArticle

Solmesky, LJ, Khazanov, N, Senderowitz, H, Wang, P, Minassian, BA, Ferreira, IM, Yue, WW, Lossos, A, Weil, M & Kakhlon, O 2017, 'A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease', Biochemical Journal, vol. 474, no. 20, pp. 3403-3420. https://doi.org/10.1042/BCJ20170469
Solmesky, Leonardo J. ; Khazanov, Netaly ; Senderowitz, Hanoch ; Wang, Peixiang ; Minassian, Berge A. ; Ferreira, Igor M. ; Yue, Wyatt W. ; Lossos, Alexander ; Weil, Miguel ; Kakhlon, Or. / A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease. In: Biochemical Journal. 2017 ; Vol. 474, No. 20. pp. 3403-3420.
@article{3f514aab9ed549e5b4709690e7db6f56,
title = "A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease",
abstract = "Glycogen storage disorders (GSDs) are caused by excessive accumulation of glycogen. Some GSDs [adult polyglucosan (PG) body disease (APBD), and Tarui and Lafora diseases] are caused by intracellular accumulation of insoluble inclusions, called PG bodies (PBs), which are chiefly composed of malconstructed glycogen. We developed an APBD patient skin fibroblast cell-based assay for PB identification, where the bodies are identified as amylase-resistant periodic acid–Schiff’s-stained structures, and quantified. We screened the DIVERSet CL 10 084 compound library using this assay in high-throughput format and discovered 11 dose-dependent and 8 non-dose-dependent PB-reducing hits. Approximately 70{\%} of the hits appear to act through reducing glycogen synthase (GS) activity, which can elongate glycogen chains and presumably promote PB generation. Some of these GS inhibiting hits were also computationally predicted to be similar to drugs interacting with the GS activator protein phosphatase 1. Our work paves the way to discovering medications for the treatment of PB-involving GSD, which are extremely severe or fatal disorders.",
author = "Solmesky, {Leonardo J.} and Netaly Khazanov and Hanoch Senderowitz and Peixiang Wang and Minassian, {Berge A.} and Ferreira, {Igor M.} and Yue, {Wyatt W.} and Alexander Lossos and Miguel Weil and Or Kakhlon",
year = "2017",
month = "10",
day = "15",
doi = "10.1042/BCJ20170469",
language = "English (US)",
volume = "474",
pages = "3403--3420",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "20",

}

TY - JOUR

T1 - A novel image-based high-throughput screening assay discovers therapeutic candidates for adult polyglucosan body disease

AU - Solmesky, Leonardo J.

AU - Khazanov, Netaly

AU - Senderowitz, Hanoch

AU - Wang, Peixiang

AU - Minassian, Berge A.

AU - Ferreira, Igor M.

AU - Yue, Wyatt W.

AU - Lossos, Alexander

AU - Weil, Miguel

AU - Kakhlon, Or

PY - 2017/10/15

Y1 - 2017/10/15

N2 - Glycogen storage disorders (GSDs) are caused by excessive accumulation of glycogen. Some GSDs [adult polyglucosan (PG) body disease (APBD), and Tarui and Lafora diseases] are caused by intracellular accumulation of insoluble inclusions, called PG bodies (PBs), which are chiefly composed of malconstructed glycogen. We developed an APBD patient skin fibroblast cell-based assay for PB identification, where the bodies are identified as amylase-resistant periodic acid–Schiff’s-stained structures, and quantified. We screened the DIVERSet CL 10 084 compound library using this assay in high-throughput format and discovered 11 dose-dependent and 8 non-dose-dependent PB-reducing hits. Approximately 70% of the hits appear to act through reducing glycogen synthase (GS) activity, which can elongate glycogen chains and presumably promote PB generation. Some of these GS inhibiting hits were also computationally predicted to be similar to drugs interacting with the GS activator protein phosphatase 1. Our work paves the way to discovering medications for the treatment of PB-involving GSD, which are extremely severe or fatal disorders.

AB - Glycogen storage disorders (GSDs) are caused by excessive accumulation of glycogen. Some GSDs [adult polyglucosan (PG) body disease (APBD), and Tarui and Lafora diseases] are caused by intracellular accumulation of insoluble inclusions, called PG bodies (PBs), which are chiefly composed of malconstructed glycogen. We developed an APBD patient skin fibroblast cell-based assay for PB identification, where the bodies are identified as amylase-resistant periodic acid–Schiff’s-stained structures, and quantified. We screened the DIVERSet CL 10 084 compound library using this assay in high-throughput format and discovered 11 dose-dependent and 8 non-dose-dependent PB-reducing hits. Approximately 70% of the hits appear to act through reducing glycogen synthase (GS) activity, which can elongate glycogen chains and presumably promote PB generation. Some of these GS inhibiting hits were also computationally predicted to be similar to drugs interacting with the GS activator protein phosphatase 1. Our work paves the way to discovering medications for the treatment of PB-involving GSD, which are extremely severe or fatal disorders.

UR - http://www.scopus.com/inward/record.url?scp=85031041193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031041193&partnerID=8YFLogxK

U2 - 10.1042/BCJ20170469

DO - 10.1042/BCJ20170469

M3 - Article

VL - 474

SP - 3403

EP - 3420

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 20

ER -